previously to be devoid of N-glycolylation 11 ( fig. 1A ). We immunized mice against ovalbumin 1 0 8 (OVA, an exemplary antigen) with our CFAs, and also with incomplete Freund's adjuvant (IFA, focused on CD4+CD8-cells because they could significantly produce different cytokines (IL-4, 1 1 2 IL-10 and IL-17A in addition to IFN-γ) . CD4+CD8-cells were generally the majority OVA-1 1 3 specific IFN-γ producing lymph node cell population and showed greater difference between 1 1 4 CFA and IFA immunized mice in terms of OVA-specific IFN-γ (not shown). CD4+CD8-cell 1 1 5 responses also correlated very well with IFN-γ ELISpot when tested (not shown). Maximum OVA-specific IFN-γ production from CD4+ T cells was depended on mycobacteria and namH; 1 1 7 OVA-specific IL-17A was strongly dependent on mycobacteria, but did not depend on namH antigen-specific IFN-γ in CD4+ cells ( fig. S3 ). OVA-specific IL-4 and IL-10 were weakly 1 2 2 dependent on mycobacteria, but not clearly on namH (fig. S2 ). This is consistent with the 1 2 3 hypothesized role for mycobacteria being a key ingredient in CFA for eliciting CMI, and that 1 2 4 mycobacterial PGN modification by NamH makes a more potent adjuvant. Host Nod2 is required for complete mycobacterial adjuvancy 1 2 7 1 2 8
Recognition of mycobacteria during live infection requires the host molecule NOD2 24 . Because we hypothesize mycobacterial PGN plays a role in CFA adjuvancy, specifically the 1 3 0 MDP motif where N-glycolylation occurs, we addressed whether the PGN/MDP sensor NOD2 is 1 3 1 1 3 9 corroborate the role for NOD2 and accordingly mycobacterial PGN in the ability of CFA to elicit 1 4 0 CMI. In the absence of Nod2, the adjuvant effect of mycobacteria declined partially, but not 1 4 5 completely. Therefore, there is other mycobacterial MAMP recognition besides that through 1 4 6 NOD2 which is important for the remainder CFA adjuvancy. Others have indicated that Mincle-1 4 7 mediated recognition of TDM contributes to mycobacterial adjuvancy 17 . We tested the By examining cytokine production from dendritic cells in vitro, it became apparent to us complemented IFA to test if CMI could be achieved with a completely synthetic adjuvant 1 8 1 containing these essential mycobacterial MAMPs. OVA-specific cytokine responses in CD4+ 1 8 2 cells were higher with increasing doses of GlcC14C18 over a 30 µg N-glycolyl MDP dose, the CFA level at the tested doses, but IL-4 and IL-10 were complemented sufficiently at 10 µg course of the experiment, the average EAE score was lower with the synthetic adjuvant Therefore, GlcC14C18 and N-glycolyl MDP were sufficient to recapitulate the adjuvant effect of 2 1 2 the whole mycobacterial cell in EAE, albeit quantitatively less at the tested doses of MAMPs. Additionally, we had attempted RR-EAE with IFA + TDM + MDP previously, which produced a 2 1 4 far less compelling phenocopy of CFA (fig. S12). In our hands, the IFA + GlcC14C18 + N-2 1 5 glycolyl MDP adjuvant has both the advantage of being completely synthetic and more 2 1 6 efficacious, than the TDM-containing adjuvant. To verify if there were any overt qualitative histopathological differences in EAE 2 1 9 between CFA and the synthetic adjuvant, we examined spinal cords from three mice from each 2 2 0 adjuvant group, having EAE scores 2, 3 and 3.5 at harvest (disease profile of these mice in fig. variable was EAE score, not adjuvant. Overall, we were not able to detect any overt differences in the autoimmune pathology created by IFA + GlcC14C18 + MDP compared to the gold 2 2 8 standard CFA. Extrapolating histopathological data to all 30 the mice in our experiment, we 2 2 9 would expect however that the synthetic adjuvant produced less pathology in the spinal cord on 2 3 0 6 average since EAE scores were lower on average. Whether this quantitative difference between 2 3 1 CFA and the synthetic formulation can be reduced with rigorous dose optimization is unclear. The ability of an adjuvant to elicit CMI can depend on ligand-receptor interactions, 2 3 6 specifically MAMP-PRR interactions. It is well appreciated since the hypothesis of Charles 2 3 7 Janeway Jr. that the host decision to mount an adaptive immune response requires genetically 2 3 8 inborn sensors to detect the presence of microbial products, or microbes by association, and that 2 3 9 this is the foundation of classical adjuvants including CFA 26 . These interactions can be thought 2 4 0 of as an "arms race" between host and microbe, originating through antagonistic evolution in the 2 4 1 case of immune evasion 27 . Additionally, we can imagine the case where a microbe might evolve 2 4 2 to increase a specific PRR interaction that favours a specific active immunological environment The immune response to mycobacteria has been attributed to its unique cell wall, especially the 2 4 6 MDP motif of PGN 6, 7, 11, 24 and TDM 17, 19 . We have shown in the context of CFA-induced 2 4 7 immunization and autoimmunity that synthetically produced N-glycolyl MDP and TDM 2 4 8 (GlcC14C18) can contribute synergistically to recapitulate the mycobacterial adjuvant effect. There are also other mycobacterial MAMPs previously identified (and likely more yet 2 5 1 unidentified), plus a greater number of PRRs linked to these microbial products. The extent to 2 5 2 which some these MAMPs contribute to mycobacterial adjuvancy may be the subject of our recently shown to elicit EAE in mice, dependent on the host C-type lectin Dectin-2 (Clec4n), at a 2 5 5 dose of 500 µg per animal 28 . Of note, we were not able yet to produce synthetic mimics of ManLAM that induce Dectin-2 signaling 29 . Similarly, purified TDM has been used to elicit 2 5 7 EAE at 500 µg per mouse, mostly dependent on MCL (Clec4d) and partially on Mincle (Clec4e) 2 5 8 19 . These findings support a role for mycobacterial MAMPs driving the CFA effect, but with the 2 5 9 requirement of purifying biologically-sourced MAMPs and such high doses, we are concerned 2 6 0 that these phenotypes might be partly driven by the inclusion of other contaminating MAMPs, 2 6 1 which we have shown can have activity between 1-10 µg in vivo when used synergistically (i.e. 2 6 2 even 1% impurity could alter results). TLR-2 has been documented to interact with multiple 2 6 3 mycobacterial lipids 30 . TLR-2 knockout mice have been used in EAE, but the literature is have cytosolic access to activate cGAS/STING. The IFA fraction perhaps could deliver MAMPs 2 6 8 across membranes. TLR-9 also senses DNA, and appears to play a role during M. tuberculosis 2 6 9 infection in mice 37 , and in humans 38 . TLR-9 was also shown to be necessary for full induction 2 7 0 of EAE 31, 33 . As synthetic DNA is available, pursuing the role of DNA in mycobacterial 2 7 1 adjuvancy interests us, perhaps as a third synthetic MAMP to work with MDP and GlcC14C18. Gram negative bacteria, not mycobacteria. We concede that many microbes likely contain 2 7 7
MAMPs able to elicit CMI; here we have concerned ourselves primarily with the history of 2 7 8 mycobacterial adjuvancy and Jules Freund. It is conceivable that a combination of MAMPs 2 7 9 from different bacteria could elicit 'unnatural' immunity that may be beneficial to control certain 2 8 0 infectious agents that otherwise evade natural immune responses. Other groups have supported a role for TDM in mycobacterial adjuvancy 17, 19 . TDM 3 0 3 together with purified PGN was shown to synergistically promote IL-17 production from OVA- allowed us to infer that CFA adjuvancy required TDM for maximal effect for different Th- MAMPs is decreased. Nevertheless, we have shown Mincle signalling is essential for full CFA 3 1 3 adjuvancy. While in vitro assays showed clear synergy between TDM and MDP, in vivo experiments were limited by overt immunopathology from TDM. That TDM was able to synergize with MDP drove us to test GlcC14C18, which had been branded as a similarly efficacious, but non- recapitulate CFA in the OVA model. Note also that the individual MAMPs had limited effect,
and only together substantially showed complementation of IFA. This 'synergy' has excited us, while CFA immunized Nod2-/-and Mincle-/-mice showed only small, generally insignificant 3 2 5 defects for IL-4 and IL-10 compared to wild-type. Natural TDM might lack promotion of IL-3 2 6 4/IL-10 axes of Th immunity, consistent with the observed 'toxicity'. IFN-γ and IL-17A were 3 2 7
not fully complemented with the tested doses of MDP and GlcC14C18. An optimal, or 3 2 8 mycobacterial-representative, dose of these MAMPs may not have been reached. With the 3 2 9 complexity of two MAMPs and the biological variability in our model, we did not find clearly 3 3 0 better doses than those tested in EAE. Other mycobacterial MAMPs may be necessary to fully 3 3 1 recapitulate the adjuvant effect of whole mycobacteria, which have been mentioned above. With the wholly synthetic formulation of 10 µg GlcC14C18 plus 30 µg N-glycolyl MDP, 3 3 4
we were able to induce RR-EAE in mice that was qualitatively indistinguishable from that was also less potent in the OVA model than the synthetic formulation, further indicating 3 4 0 correlation between these readouts (not shown). CFA often needs to be 'titrated' to account for progressive EAE is necessary for studies, rather than relapsing-remitting EAE 40 . These facts 3 4 5 point to dosing as a means of controlling the degree of EAE, which may also be true with the specific antibodies. CIA generally takes longer and has a greater role for humoral immunity than 3 5 0 EAE which is T-cell driven, (our interest was in CMI for this study) 41 . Wherever mycobacterial 3 5 1 adjuvancy is useful, we suspect a synthetic adjuvant could be beneficial. Indeed, intravesical 3 5 2 injection of BCG is used to treat bladder cancer (i.e. BCG can provide MAMP-driven protection, 3 5 3 not simply antigen-specific protection). Furthermore, BCG administration to millions of babies 3 5 4 each year can protect not just against childhood tuberculosis, but non-specifically against other 3 5 5 diseases 42 . Our work demonstrates that mycobacterial NOD2 and Mincle ligands contribute to the for ~40 hours at 37 o C 5% CO 2 , Brefeldin A (GolgiPlug TM , BD) was added for an additional 5 4 0 5 hours, and then cells were stained and fixed (BD fixation/permeabilization buffer) for flow 4 0 6 cytometry on ice. Intracellular staining was performed on the same or the next day using BD about one week, EAE was scored blinded (i.e. the scorer did not know the adjuvant received by 4 2 1 the mouse) every day according to these cumulative criteria: 0, no paralysis (normal); 0.5, partial or both hind limbs plus trunk weakness; 5, weakness or paralysis of forelimbs; 6, found dead. At the end of EAE scoring, the experiment was un-blinded and three mice from each group with 4 3 4 matching scores were selected. These six mice were anesthetized with peritoneal ketamine Americans. J Infect Dis 197, 1713-1716 (2008) . azidonitration/reduction. Org Biomol Chem 13, 1515-1520 (2015) . Natl Acad Sci U S A 114, 2675-2680 (2017) . Immunology 180, 7404-7413 (2008) . two independent experiments, from individual mice with averages +/-SEM. p-values were 6 5 0 calculated with two-tailed student's t-tests. *p<0.05; **p<0.01; ns, not significant, p>0.05. For 6 5 1 CFA Nod2+/+, CFA Nod2-/-, IFA Nod2+/+ and IFA Nod2-/-, N = 12, 13, 9 and 7, respectively. GlcC14C18 in IFA-PBS emulsion. Pictures are representative of 3 mice per group. GlcC14C18 (N=7), IFA + 30 µg N-glycolyl MDP + 30 µg GlcC14C18 (N=7), or CFA (N=7). GlcC14C18 + 30 µg N-glycolyl MDP (N=15). Mice were euthanized on day 28 post injection. days. Lines represent averages +/-SEM. p-value was calculated with two-tailed student's t- Bone marrow was extracted from mice by flushing femora and tibiae with PBS + 2% BSA + 2% 7 0 5 glucose using a 25-G syringe. Red blood cells were lysed and remaining bone marrow cells 7 0 6 were filtered through 70 µm cell strainer. Cells were cultured at 500,000 cells / ml R10 with 20 7 0 7 ng/ml murine rGM-CSF (PeproTech); cells were fed on day 3 with R10 + rGM-CSF, and on day 7 0 8 6 with R10 alone. On day 7, loosely adherent cells were harvested by gentle pipetting and used 7 0 9 in assays. legend for details). p-values were calculated with two-tailed student's t-tests. produced in an independent experiment. p-values were calculated with two-tailed student's t- Mincle. These data are from the same set shown in fig. 3 (refer to fig. 3 legend for details). pathology over time (scores were given by these criteria: 0, normal; 1, any mark/discoloration at 7 4 4 site; 2, obvious swelling; 3, 2+abnormal skin). B, scores from A for each day added together. 50 ng/well of TDM or GlcC14C18 by dissolving in isopropanol and drying (lipid-free conditions 7 5 0 used wells treated with isopropanol alone). Where present, MDP is 1 µg/ml. BMDCs were 7 5 1 incubated with stimulants for 6 hours at 37 o C, 5% CO 2 before supernatant was removed for 7 5 2 ELISA analysis. Shown are averages +/-SEM of 3-6 individually stimulated and assayed wells. wild-type mice immunized against OVA seven days prior with IFA (N=4), IFA + 10 µg 
